Repare Raises $68M in Series A to Develop CRISPR-Based Synthetic Lethality Platform – Genetic Engineering & Biotechnology News (blog)
Xconomy |
Repare Raises $68M in Series A to Develop CRISPR-Based Synthetic Lethality Platform
Genetic Engineering & Biotechnology News (blog) Versant Venture and MPM Capital co-led a $68-million Series A fundraising round to establish Repare Therapeutics, a Canada-based cancer drug company exploiting a high-throughput, CRISPR-based screening platform to identify synthetic lethality cancer … Celgene-backed cancer biotech Repare emerges from stealth with $68M Repare Nabs $68M To Find Synthetic Lethal Cancer Targets Beyond PARP Repare Therapeutics Raises US$68 Million Series A |
